Advertisement

The association between patients’ perceived continuity of care and beliefs about oral anticancer treatment

  • Orit Cohen CastelEmail author
  • Efrat Shadmi
  • Lital Keinan–Boker
  • Tal Granot
  • Khaled Karkabi
  • Efrat Dagan
Original Article
  • 32 Downloads

Abstract

Purpose

To explore factors associated with necessity beliefs and concerns among patients receiving oral anticancer therapy (OACT) and, specifically, to examine the relationship between continuity of care (COC) and patients’ beliefs about OACT.

Methods

A cross-sectional study was conducted among patients from four oncology centers receiving OACT (either targeted, hormonal, or chemotherapy). Two months after OACT initiation, patients were asked to participate in a face-to-face or telephone survey. The Beliefs about Medicines Questionnaire was used to examine patients’ perceptions of their personal necessity for OACT and concerns about potential adverse effects. The Nijmegen Continuity Questionnaire was used to assess patients’ perceived COC. Data on clinical characteristics were collected from medical records.

Results

Participants’ beliefs about OACT necessity (n = 91) were found to be associated with COC within the oncology team, and with COC between the oncology specialist and the primary care physicians (β = 0.27, p = 0.003; β = 0.22, p = 0.02, respectively), beyond age, depression, and cancer type (ΔR2 = 0.14, p < 0.001). Additionally, the difference between participants’ beliefs about OACT necessity and their OACT-related concerns was associated with COC within the oncology team (β = 0.30, p = 0.001), beyond age, income, family status, and cancer type (ΔR2 = 0.09, p = 0.001).

Conclusions

This study shows that cancer patients’ perceptions about the COC between care providers are related to their beliefs about OACT necessity, thus providing evidence for the importance of health care delivery approaches that support COC within the oncology team and between the oncology specialist and the primary care physician.

Keywords

Oral anticancer treatment Continuity of care Beliefs about Medicines Questionnaire Nijmegen Continuity Questionnaire 

Notes

Acknowledgments

The authors express their gratitude to patients who participated in this study and made this research possible.

Funding

This study was supported by grants from the Israel Cancer Association (grant no. (20140089, the National Institute for Health Policy Research (IL) (grant no. (2015/84, and Maccabi Institute for Health Services Research (grant no.28/2016).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interests.

Supplementary material

520_2019_4668_MOESM1_ESM.docx (21 kb)
ESM 1 (DOCX 20 kb)

References

  1. 1.
    Timmers L, Beckeringh JJ, van Herk-Sukel MP, Boven E, Hugtenburg JG (2012) Use and costs of oral anticancer agents in the Netherlands in the period 2000–2008. Pharmacoepidemiol Drug Saf 21(10):1036–1044.  https://doi.org/10.1002/pds.2225 CrossRefGoogle Scholar
  2. 2.
    Schneider SM, Hess K, Gosselin T (2011) Interventions to promote adherence with oral agents. Semin Oncol Nurs 27(2):133–141.  https://doi.org/10.1016/j.soncn.2011.02.005 CrossRefGoogle Scholar
  3. 3.
    Liu G, Franssen E, Fitch MI, Warner E (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15(1):110–115CrossRefGoogle Scholar
  4. 4.
    Seal BS, Anderson S, Shermock KM (2016) Factors associated with adherence rates for oral and intravenous anticancer therapy in commercially insured patients with metastatic colon cancer. J Managed Care Specialty Pharm 22(3):227–235.  https://doi.org/10.18553/jmcp.2016.22.3.227 CrossRefGoogle Scholar
  5. 5.
    Kripalani S, LeFevre F, Phillips CO, Williams MV, Basaviah P, Baker DW (2007) Deficits in communication and information transfer between hospital-based and primary care physicians: implications for patient safety and continuity of care. JAMA 297(8):831–841.  https://doi.org/10.1001/jama.297.8.831 CrossRefGoogle Scholar
  6. 6.
    Ganesan P, Sagar TG, Dubashi B, Rajendranath R, Kannan K, Cyriac S, Nandennavar M (2011) Nonadherence to Imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol 86(6):471–474.  https://doi.org/10.1002/ajh.22019 CrossRefGoogle Scholar
  7. 7.
    Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C (2013) Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 108(7):1515–1524.  https://doi.org/10.1038/bjc.2013.116 CrossRefGoogle Scholar
  8. 8.
    Verbrugghe M, Verhaeghe S, Lauwaert K, Beeckman D, Van Hecke A (2013) Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review. Cancer Treatment Rev 39(6):610–621.  https://doi.org/10.1016/j.ctrv.2012.12.014 CrossRefGoogle Scholar
  9. 9.
    Mathes T, Pieper D, Antoine SL, Eikermann M (2014) Adherence influencing factors in patients taking oral anticancer agents: a systematic review. Cancer Epidemiol 38:214–226.  https://doi.org/10.1016/j.canep.2014.03.012 CrossRefGoogle Scholar
  10. 10.
    Lin C, Clark R, Tu P, Bosworth HB, Zullig LL (2017) Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers. Breast Cancer Res Treatment 165(2):247–260.  https://doi.org/10.1007/s10549-017-4317-2 CrossRefGoogle Scholar
  11. 11.
    Janz NK, Becker MH (1984) The health belief model: a decade later. Health Ed Quart 11(1):1–47.  https://doi.org/10.1177/109019818401100101 CrossRefGoogle Scholar
  12. 12.
    Holmes EAF, Hughes DA, Morrison VL (2014) Predicting adherence to medications using health psychology theories: a systematic review of 20 years of empirical research. Value Health 17(8):863–876.  https://doi.org/10.1016/j.jval.2014.08.2671 CrossRefGoogle Scholar
  13. 13.
    Lehane E, McCarthy G (2007) An examination of the intentional and unintentional aspects of medication non-adherence in patients diagnosed with hypertension. J Clin Nurs 16(4):698–706.  https://doi.org/10.1111/j.1365-2702.2005.01538.x CrossRefGoogle Scholar
  14. 14.
    Gadkari AS, McHorney CA (2012) Unintentional non-adherence to chronic prescription medications: how unintentional is it really? BMC Health Serv Res 12:98.  https://doi.org/10.1186/1472-6963-12-98 CrossRefGoogle Scholar
  15. 15.
    Horne R, Weinman J (1999) Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 47(6):555–567CrossRefGoogle Scholar
  16. 16.
    Horne R, Chapman SC, Parham R, Freemantle N, Forbes A, Cooper V (2013) Understanding patients’ adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the necessity-concerns framework. PLoS One 8(12):e80633.  https://doi.org/10.1371/journal.pone.0080633 CrossRefGoogle Scholar
  17. 17.
    Foot H, La Caze A, Gujral G, Cottrell N (2016) The necessity-concerns framework predicts adherence to medication in multiple illness conditions: a meta-analysis. Patient Educ Couns 99(5):706–717.  https://doi.org/10.1016/j.pec.2015.11.004 CrossRefGoogle Scholar
  18. 18.
    Butler JA, Peveler RC, Roderick P, Smith PW, Horne R, Mason JC (2004) Modifiable risk factors for non-adherence to immunosuppressants in renal transplant recipients: a cross-sectional study. Nephrol Dial Transplant 19(12):3144–3149.  https://doi.org/10.1093/ndt/gfh505 CrossRefGoogle Scholar
  19. 19.
    Jacob Arriola KR, Mason TA, Bannon KA, Holmes C, Powell CL, Horne K, O’Regan R (2014) Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients. Patient Educ Couns 95(1):98–103.  https://doi.org/10.1016/j.pec.2013.12.019 CrossRefGoogle Scholar
  20. 20.
    Haggerty JL, Reid RJ, Freeman GK, Starfield BH, Adair CE, McKendry R (2003) Continuity of care: a multidisciplinary review. BMJ 327(7425):1219–1221.  https://doi.org/10.1136/bmj.327.7425.1219 CrossRefGoogle Scholar
  21. 21.
    Dossett LA, Hudson JN, Morris AM, Lee MC, Roetzheim RG, Fetters MD, Quinn GP (2017) The primary care provider (PCP)-cancer specialist relationship: systematic review and mixed-methods meta-synthesis. CA Cancer J Clin 67(2):156–169.  https://doi.org/10.3322/caac.21385 CrossRefGoogle Scholar
  22. 22.
    Uijen AA, Schers HJ, Schellevis FG, Mokkink HG, van Weel C, van den Bosch WJ (2012) Measuring continuity of care: psychometric properties of the Nijmegen Continuity Questionnaire. Br J Gen Pract 62(600):e949–e957.  https://doi.org/10.3399/bjgp12X652364 CrossRefGoogle Scholar
  23. 23.
    Snyder CF, Earle CC, Herbert RJ, Neville BA, Blackford AL, Frick KD (2008) Trends in follow-up and preventive care for colorectal cancer survivors. J Gen Int Med 23(3):254–259.  https://doi.org/10.1007/s11606-007-0497-5 CrossRefGoogle Scholar
  24. 24.
    Husain A, Barbera L, Howell D, Moineddin R, Bezjak A, Sussman J (2013) Advanced lung cancer patients’ experience with continuity of care and supportive care needs. Support Care Cancer 21(5):1351–1358.  https://doi.org/10.1007/s00520-012-1673-7 CrossRefGoogle Scholar
  25. 25.
    Weingart SN, Brown E, Bach PB, Eng K, Johnson SA, Kuzel TM, Langbaum TS, Leedy RD, Muller RJ, Newcomer LN, O’Brien S, Reinke D, Rubino M, Saltz L, Walters RS (2008) NCCN task force report: oral chemotherapy. J Natl Compr Cancer Netw 6(Suppl 3):S1–S14Google Scholar
  26. 26.
    Cohen J (1992) A power primer. Psychol Bull 112(1):155–159CrossRefGoogle Scholar
  27. 27.
    Channa Y, Shabo V (2012) Israel household expenditure survey and income survey 2010. Central Bureau of Statistics.http://www.cbs.gov.il/www/statistical/home10_e.pdf. Accessed 8 Sept 2018
  28. 28.
    Geulayov G, Jungerman T, Moses S, Friedman N, Miron R, Gross R (2009) Assessing the psychometric properties of the mood module of the Patient Health Questionnaire in primary care in Israel. Isr J Psychiatry Relat Sci 46:36Google Scholar
  29. 29.
    Bhattacharya D, Easthall C, Willoughby KA, Small M, Watson S (2012) Capecitabine non-adherence: exploration of magnitude, nature and contributing factors. J Oncol Pharm Pract 18(3):333–342.  https://doi.org/10.1177/1078155211436022 CrossRefGoogle Scholar
  30. 30.
    Horne R, Weinman J, Hankins M (1999) The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 14(1):1–24.  https://doi.org/10.1080/08870449908407311 CrossRefGoogle Scholar
  31. 31.
    Uijen AA, Schellevis FG, van den Bosch WJ, Mokkink HG, van Weel C, Schers HJ (2011) Nijmegen Continuity Questionnaire: development and testing of a questionnaire that measures continuity of care. J Clin Epidemiol 64(12):1391–1399.  https://doi.org/10.1016/j.jclinepi.2011.03.006 CrossRefGoogle Scholar
  32. 32.
    Cohen Castel O, Dagan E, Keinan-Boker L, Shadmi E (2018) Reliability and validity of the Hebrew version of the Nijmegen Continuity Questionnaire for measuring patients’ perceived continuity of care in oral anticancer therapy. Eur J Cancer Care (Engl) 27(6):e12913.  https://doi.org/10.1111/ecc.12913 CrossRefGoogle Scholar
  33. 33.
    Kroenke K, Spitzer RL, Williams JB (2001) The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 16(9):606–613CrossRefGoogle Scholar
  34. 34.
    Foglino S, Bravi F, Carretta E, Fantini MP, Dobrow MJ, Brown AD (2016) The relationship between integrated care and cancer patient experience: a scoping review of the evidence. Health Policy 120(1):55–63.  https://doi.org/10.1016/j.healthpol.2015.12.004 CrossRefGoogle Scholar
  35. 35.
    Komatsu H, Nakayama K, Togari T, Suzuki K, Hayashi N, Murakami Y, Iioka Y, Osaka W, Yagasaki K, Nakamura S, Neumann J, Ueno NT (2011) Information sharing and case conference among the multidisciplinary team improve patients’ perceptions of care. Open Nurs J 5:79–85.  https://doi.org/10.2174/1874434601105010079 CrossRefGoogle Scholar
  36. 36.
    Nielsen JD, Palshof T, Mainz J, Jensen AB, Olesen F (2003) Randomised controlled trial of a shared care programme for newly referred cancer patients: bridging the gap between general practice and hospital. Qual Saf Health Care 12(4):263–272CrossRefGoogle Scholar
  37. 37.
    Timmers L, Boons CC, Mangnus D, Van de Ven PM, Van den Berg PH, Beeker A, Swart EL, Honeywell RJ, Peters GJ, Boven E, Hugtenburg JG (2016) Adherence and patients’ experiences with the use of capecitabine in daily practice. Front Pharmacol 7:310.  https://doi.org/10.3389/fphar.2016.00310 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.The Cheryl Spencer Department of Nursing, Faculty of Social Welfare and Health SciencesUniversity of HaifaHaifaIsrael
  2. 2.School of Public Health, Faculty of Social Welfare and Health SciencesUniversity of HaifaHaifaIsrael
  3. 3.Davidoff Cancer Treatment and Research CenterRabin Medical CenterPetah TikvaIsrael
  4. 4.Department of Family Medicine, Clalit Health Services, Haifa & Western Galilee District, Ruth & Bruce Rappaport Faculty of MedicineTechnion - Israel Institute of TechnologyHaifaIsrael

Personalised recommendations